Current Diabetes Technology and its Challenges
Yıl: 2022 Cilt: 26 Sayı: 1 Sayfa Aralığı: 38 - 47 Metin Dili: İngilizce İndeks Tarihi: 26-06-2022
Current Diabetes Technology and its Challenges
Öz: The prevalence of diabetes mellitus is increasing at an alarming rate worldwide. With no cure available, effective disease management is the best way to control disease
progression. Studies have shown that diabetes technology
helps to improve health outcomes and the quality of life of
the patients. Diabetes technology can be defined as any solution encompassing hardware, devices, and software used
in the disease management of patients. This review serves
as an introduction to diabetes mellitus by discussing the different categories of well-established diabetes technology,
related ongoing research, and its challenges. This review is
divided into 3 main categories, insulin administration, glucose monitoring, and hybrid devices that combine the 2 categories into one. Digital health application is also discussed
as it is becoming a notable tool in the disease management
of diabetes. Widespread use of these devices in disease management has been increasing in recent years. However,
there are still barriers that prevent the utilization of the full
potential of these devices.
Anahtar Kelime: Güncel Diyabet Teknolojisi ve Zorlukları
Öz: Diabetes mellitus prevalansı dünya çapında endişe verici bir
oranda artmaktadır. Kesin tedavi mevcut olmadığında, hastalığın ilerlemesini kontrol etmenin en iyi yolu etkili hastalık
yönetimidir. Araştırmalar, diyabet teknolojisinin sağlık sonuçlarını ve hastaların yaşam kalitesini iyileştirmeye yardımcı olduğunu göstermiştir. Diyabet teknolojisi, hastaların
hastalık yönetiminde kullanılan donanım, cihaz ve yazılımları kapsayan her türlü çözüm olarak tanımlanabilir. Bu derleme, iyi bilinen diyabet teknolojisinin farklı kategorilerini,
konuyla ilgili sürmekte olan araştırmaları ve zorlukları tartışarak diabetes mellitusa bir giriş görevi görmektedir. Derlememiz, insülin uygulaması, glukoz izleme ve 2 kategoriyi
tek bir kategoride birleştiren hibrit cihazlar olmak üzere 3
ana kategoriye ayrılmıştır. Ayrıca diyabet, hastalık yönetiminde dikkate değer bir araç hâline geldiği için dijital sağlık
uygulaması da ele alınmıştır. Bu cihazların hastalık yönetiminde kullanımı son yıllarda giderek yaygınlaşmaktadır.
Ancak yine de cihazların tam potansiyelinden yararlanılmasının önünde engeller bulunmaktadır.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
- 1. Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, Malanda B. IDF Diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271-281. [Crossref] [Pubmed]
- 2. Daneman D. Type 1 diabetes. Lancet. 2006; 367:847-858. [Crossref] [Pubmed]
- 3. Dabelea D, Mayer-Davis EJ, Saydah S, Imperatore G, Linder B, Divers J, Bell R, Badaru A, Talton JW, Crume T, Liese AD, Merchant AT, Lawrence JM, Reynolds K, Dolan L, Liu LL, Hamman RF; SEARCH for Diabetes in Youth Study. Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009. JAMA. 2014;311:1778- 1786. [Crossref] [Pubmed] [PMC]
- 4. Ali O. Genetics of type 2 diabetes. World J Diabetes. 2013;4:114-123. [Crossref] [Pubmed] [PMC]
- 5. Kharroubi AT, Darwish HM. Diabetes mellitus: the epidemic of the century. World J Diabetes. 2015; 6:850-867. [Crossref] [Pubmed] [PMC]
- 6. American Diabetes Association. 7. Diabetes technology: standards of medical care in diabetes-2020. Diabetes Care. 2020;43:S77-S88. Erratum in: Diabetes Care. 2020;43:1981. [Crossref] [Pubmed]
- 7. Shah RB, Patel M, Maahs DM, Shah VN. Insulin delivery methods: past, present and future. Int J Pharm Investig. 2016;6:1-9. [Crossref] [Pubmed] [PMC]
- 8. Hyllested-Winge J, Jensen KH, Rex J. A review of 25 years' experience with the NovoPen family of insulin pens in the management of diabetes mellitus. Clin Drug Investig. 2010;30:643-674. [Crossref] [Pubmed]
- 9. Selam JL. Evolution of diabetes insulin delivery devices. J Diabetes Sci Technol. 2010;4:505-513. [Crossref] [Pubmed] [PMC]
- 10.Adolfsson P, Hartvig NV, Kaas A, Møller JB, Hellman J. Increased time in range and fewer missed bolus injections after introduction of a smart connected insulin pen. Diabetes Technol Ther. 2020;22:709- 718. [Crossref] [Pubmed] [PMC]
- 11. Gross TM, Kayne D, King A, Rother C, Juth S. A bolus calculator is an effective means of controlling postprandial glycemia in patients on insulin pump therapy. Diabetes Technol Ther. 2003;5:365-369. [Crossref] [Pubmed]
- 12. Fry A. Insulin delivery device technology 2012: where are we after 90 years? J Diabetes Sci Technol. 2012;6:947-953. [Crossref] [Pubmed] [PMC]
- 13.Sharma G, Sharma AR, Nam JS, Doss GP, Lee SS, Chakraborty C. Nanoparticle based insulin delivery system: the next generation efficient therapy for Type 1 diabetes. J Nanobiotechnology. 2015;13:74. [Crossref] [Pubmed] [PMC]
- 14.Ackermann RT, Wallia A, Kang R, Cooper A, Prospect TA, Sandy LG, Vojta D. Comparative effectiveness and costs of insulin pump therapy for diabetes. Am J Manag Care. 2017;23:353-359. [Pubmed]
- 15. Paris CA, Imperatore G, Klingensmith G, Petitti D, Rodriguez B, Anderson AM, Schwartz ID, Standiford DA, Pihoker C. Predictors of insulin regimens and impact on outcomes in youth with type 1 diabetes: the SEARCH for Diabetes in Youth study. J Pediatr. 2009;155:183-9.e1. [Crossref] [Pubmed]
- 16. Ratheau L, Jeandidier N, Moreau F, Sigrist S, Pinget M. How technology has changed diabetes management and what it has failed to achieve. Diabetes Metab. 2011;37 Suppl 4:S57-64. [Crossref] [Pubmed]
- 17. Ziegler R, Heidtmann B, Hilgard D, Hofer S, Rosenbauer J, Holl R; DPV-Wiss-Initiative. Frequency of SMBG correlates with HbA1c and acute complications in children and adolescents with type 1 diabetes. Pediatr Diabetes. 2011;12:11-17. [Crossref] [Pubmed]
- 18.Benjamin EM. Self-monitoring of blood glucose: the basics. Clinical Diabetes. 2002;20:45-47. [Crossref]
- 19.Mancini G, Berioli MG, Santi E, Rogari F, Toni G, Tascini G, Crispoldi R, Ceccarini G, Esposito S. Flash glucose monitoring: a review of the literature with a special focus on type 1 diabetes. Nutrients. 2018;10:992. [Crossref] [Pubmed] [PMC]
- 20.Chen C, Zhao XL, Li ZH, Zhu ZG, Qian SH, Flewitt AJ. Current and emerging technology for continuous glucose monitoring. Sensors (Basel). 2017;17: 182. [Crossref] [Pubmed] [PMC]
- 21.Klonoff DC, Ahn D, Drincic A. Continuous glucose monitoring: a review of the technology and clinical use. Diabetes Res Clin Pract. 2017;133:178-192. [Crossref] [Pubmed]
- 22.Vigersky RA. The benefits, limitations, and cost-effectiveness of advanced technologies in the management of patients with diabetes mellitus. J Diabetes Sci Technol. 2015;9:320-330. [Crossref] [Pubmed] [PMC]
- 23.Kamann S, Aerts O, Heinemann L. Further evidence of severe allergic contact dermatitis from isobornyl acrylate while using a continuous glucose monitoring system. J Diabetes Sci Technol. 2018;12:630- 633. [Crossref] [Pubmed] [PMC]
- 24. Danne T, Nimri R, Battelino T, Bergenstal RM, Close KL, DeVries JH, Garg S, Heinemann L, Hirsch I, Amiel SA, Beck R, Bosi E, Buckingham B, Cobelli C, Dassau E, Doyle FJ 3rd, Heller S, Hovorka R, Jia W, Jones T, Kordonouri O, Kovatchev B, Kowalski A, Laffel L, Maahs D, Murphy HR, Nørgaard K, Parkin CG, Renard E, Saboo B, Scharf M, Tamborlane WV, Weinzimer SA, Phillip M. International consensus on use of continuous glucose monitoring. Diabetes Care. 2017;40:1631-1640. [Crossref] [Pubmed] [PMC]
- 25. Leelarathna L, Wilmot EG. Flash forward: a review of flash glucose monitoring. Diabet Med. 2018;35:472-482. [Crossref] [Pubmed]
- 26.Zhao M, Leung PS. Revisiting the use of biological fluids for noninvasive glucose detection. Future Med Chem. 2020;12:645-647. [Crossref] [Pubmed]
- 27.Bhide A, Muthukumar S, Prasad S. CLASP (Continuous lifestyle awareness through sweat platform): A novel sensor for simultaneous detection of alcohol and glucose from passive perspired sweat. Biosens Bioelectron. 2018;117:537-545. [Crossref] [Pubmed] [PMC]
- 28.Baca JT, Finegold DN, Asher SA. Tear glucose analysis for the noninvasive detection and monitoring of diabetes mellitus. Ocul Surf. 2007;5:280-293. [Crossref] [Pubmed]
- 29.Zhang J, Hodge W, Hutnick C, Wang X. Noninvasive diagnostic devices for diabetes through measuring tear glucose. J Diabetes Sci Technol. 2011;5:166- 172. [Crossref] [Pubmed] [PMC]
- 30. Gupta S, Nayak MT, Sunitha JD, Dawar G, Sinha N, Rallan NS. Correlation of salivary glucose level with blood glucose level in diabetes mellitus. J Oral Maxillofac Pathol. 2017;21:334-339. [Crossref] [Pubmed] [PMC]
- 31.Soni A, Jha SK. A paper strip based non-invasive glucose biosensor for salivary analysis. Biosens Bioelectron. 2015;67:763-768. [Crossref] [Pubmed]
- 32. Liu C, Sheng Y, Sun Y, Feng J, Wang S, Zhang J, Xu J, Jiang D. A glucose oxidase-coupled DNAzyme sensor for glucose detection in tears and saliva. Biosens Bioelectron. 2015;70:455-461. [Crossref] [Pubmed]
- 33.Moser EG, Morris AA, Garg SK. Emerging diabetes therapies and technologies. Diabetes Res Clin Pract. 2012;97:16-26. [Crossref] [Pubmed]
- 34.Akturk HK, Rewers A, Joseph H, Schneider N, Garg SK. Possible ways to improve postprandial glucose control in type 1 diabetes. Diabetes Technol Ther. 2018;20:S224-S232. [Crossref] [Pubmed]
- 35.Akturk HK, Garg S. Technological advances shaping diabetes care. Curr Opin Endocrinol Diabetes Obes. 2019;26:84-89. [Crossref] [Pubmed]
- 36. Tauschmann M, Thabit H, Bally L, Allen JM, Hartnell S, Wilinska ME, Ruan Y, Sibayan J, Kollman C, Cheng P, Beck RW, Acerini CL, Evans ML, Dunger DB, Elleri D, Campbell F, Bergenstal RM, Criego A, Shah VN, Leelarathna L, Hovorka R; APCam11 Consortium. Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial. Lancet. 2018;392:1321-1329. Erratum in: Lancet. 2018;392:1310. [Crossref] [Pubmed] [PMC]
- 37.Senn JD, Fischli S, Slahor L, Schelbert S, Henzen C. Long-term effects of initiating continuous subcutaneous insulin infusion (CSII) and continuous glucose monitoring (CGM) in people with type 1 diabetes and unsatisfactory diabetes control. J Clin Med. 2019;8:394. [Crossref] [Pubmed] [PMC]
- 38.World Health Organization. mHealth: new horizons for health through mobile technologies. Vol. 3. Geneva: WHO; 2011. [Link]
- 39. Drincic A, Prahalad P, Greenwood D, Klonoff DC. Evidence-based mobile medical applications in diabetes. Endocrinol Metab Clin North Am. 2016; 45:943-965. Erratum in: Endocrinol Metab Clin North Am. 2017;46:xix. [Crossref] [Pubmed] [PMC]
- 40. Fleming GA, Petrie JR, Bergenstal RM, Holl RW, Peters AL, Heinemann L. Diabetes digital app technology: benefits, challenges, and recommendations. A consensus report by the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) Diabetes Technology Working Group. Diabetologia. 2020;63:229-241. [Crossref] [Pubmed]
- 41.Malka R, Nathan DM, Higgins JM. Mechanistic modeling of hemoglobin glycation and red blood cell kinetics enables personalized diabetes monitoring. Sci Transl Med. 2016;8:359ra130. [Crossref] [Pubmed] [PMC]
- 42.Alcántara-Aragón V. Improving patient self-care using diabetes technologies. Ther Adv Endocrinol Metab. 2019;10:2042018818824215. [Crossref] [Pubmed] [PMC]
- 43.Scott A, Chambers D, Goyder E, O'Cathain A. Socioeconomic inequalities in mortality, morbidity and diabetes management for adults with type 1 diabetes: A systematic review. PLoS One. 2017;12: e0177210. [Crossref] [Pubmed] [PMC]
| APA | Fauzi A, chia a, Tang Y (2022). Current Diabetes Technology and its Challenges . , 38 - 47. |
| Chicago | Fauzi Ayesha,chia adeline,Tang Yin-Quan Current Diabetes Technology and its Challenges . (2022): 38 - 47. |
| MLA | Fauzi Ayesha,chia adeline,Tang Yin-Quan Current Diabetes Technology and its Challenges . , 2022, ss.38 - 47. |
| AMA | Fauzi A,chia a,Tang Y Current Diabetes Technology and its Challenges . . 2022; 38 - 47. |
| Vancouver | Fauzi A,chia a,Tang Y Current Diabetes Technology and its Challenges . . 2022; 38 - 47. |
| IEEE | Fauzi A,chia a,Tang Y "Current Diabetes Technology and its Challenges ." , ss.38 - 47, 2022. |
| ISNAD | Fauzi, Ayesha vd. "Current Diabetes Technology and its Challenges ". (2022), 38-47. |
| APA | Fauzi A, chia a, Tang Y (2022). Current Diabetes Technology and its Challenges . Turkish Journal of Endocrinology and Metabolism, 26(1), 38 - 47. |
| Chicago | Fauzi Ayesha,chia adeline,Tang Yin-Quan Current Diabetes Technology and its Challenges . Turkish Journal of Endocrinology and Metabolism 26, no.1 (2022): 38 - 47. |
| MLA | Fauzi Ayesha,chia adeline,Tang Yin-Quan Current Diabetes Technology and its Challenges . Turkish Journal of Endocrinology and Metabolism, vol.26, no.1, 2022, ss.38 - 47. |
| AMA | Fauzi A,chia a,Tang Y Current Diabetes Technology and its Challenges . Turkish Journal of Endocrinology and Metabolism. 2022; 26(1): 38 - 47. |
| Vancouver | Fauzi A,chia a,Tang Y Current Diabetes Technology and its Challenges . Turkish Journal of Endocrinology and Metabolism. 2022; 26(1): 38 - 47. |
| IEEE | Fauzi A,chia a,Tang Y "Current Diabetes Technology and its Challenges ." Turkish Journal of Endocrinology and Metabolism, 26, ss.38 - 47, 2022. |
| ISNAD | Fauzi, Ayesha vd. "Current Diabetes Technology and its Challenges ". Turkish Journal of Endocrinology and Metabolism 26/1 (2022), 38-47. |
